# US 2026/0074039 A1 · Method of Data Analysis for Long-Term Blood Glucose Concentration Trend

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0074039 A1
- Document ID: US20260074039A1
- Status: Published application
- Kind: A1
- Application number: 19/389,368
- Filed: 2025-11-14
- Published: 2026-03-12
- Earliest claimed: 2023-01-18
- Assignees: National Taiwan University
- Applicants: National Taiwan University
- Inventors: Chi-Kuang Sun; Xu-hao Ye; Tzung-Dau Wang
- Web page: https://patentgrep.com/patent/US20260074039A1

## CPC

- G16H 10/60: for patient-specific data, e.g. for electronic patient records
- G16H 40/00: ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- G16H 50/50: for simulation or modelling of medical disorders
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

A method of data analysis is provided. The method is used for finding a long-term trend of blood glucose concentration. The method builds a model for estimating long-term glycemic variability and long-term blood glucose trajectory. Based on single-erythrocyte-level glycated hemoglobin distribution, the glycemic variability is analyzed. A first analysis method is to give a number. The number shows the level of the historical glycemic variabilities. A second analysis method is to restore the blood glucose trajectory over the past 20 weeks. Based on the single-erythrocyte-level glycated hemoglobin distribution, the present invention easily assesses blood-glucose-related clinical information for about 150 days. Hence, an important complement is obtained for diabetes-related or glucose-monitoring-related clinical applications.

## Claims

### Claim 1

A method for reconstructing a subject's historical glucose concentration trajectory, G(τ), from single-cell glycated hemoglobin (HbA1c) measurements, the method comprising:
(a) obtaining a plurality of single-red-blood-cell (RBC) HbA1c fractions, {Ai}, from a total of N RBCs sampled from a subject, wherein each said HbA1c fraction (A) represents a ratio of a glycated hemoglobin amount to a total hemoglobin amount within a single RBC;
(b) generating a first RBC HbA1c distribution, PDFHbA1c(A), from said plurality of {Ai}, said first distribution being represented as a histogram with a selected bin width ΔA, wherein said ΔA is dependent on said N;
(c) defining a whole-blood RBC age probability density function, PDFAge(t), representing a statistical distribution of RBCs having a circulation age t, wherein t is the time since release from bone marrow;
(d) defining an RBC glycation model, A(t), that provides a deterministic mapping between said historical glucose concentration trajectory, G(τ), and a corresponding HbA1c fraction for an RBC of age t;
(e) determining a time resolution ΔT corresponding to said bin width ΔA, wherein said ΔT defines discrete segments for said G(τ);
(f) generating a reference RBC HbA1c distribution by: (i) establishing an initial candidate glucose trajectory, G(τ); (ii) solving said glycation model A(t) based on said candidate G(τ); and (iii) computationally transforming said PDFAge(t) into said reference RBC HbA1c distribution using the mapping provided by A(t);
(g) iteratively modifying said candidate G(τ) by: (i) calculating a deviation metric between said first RBC HbA1c distribution and said reference RBC HbA1c distribution; (ii) adjusting values of G(τ) within said discrete segments based on said deviation metric to create a new candidate G(τ); and (iii) repeating steps (f) and (g) until said deviation metric is below a predefined threshold; and
(h) outputting the final candidate G(τ) from step (g) as the reconstructed historical glucose concentration trajectory for the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein said RBC glycation model A(t) is defined by the integral equation:
A
⁡
(
t
)
=
∫
-
T
0
t
k
g
*
G
⁡
(
τ
)
*
(
1
-
A
⁡
(
τ
)
)
⁢
d
⁢
τ
.
wherein kg is a hemoglobin glycation reaction constant, T0 is a pre-circulation residence time in bone marrow, G(τ) is the glucose concentration at time τ, and an initial condition A(−T0) is zero.

### Claim 3 (depends on 2)

The method of claim 2, wherein said kg is a constant determined from a source selected from the group consisting of:
(a) a pre-determined value obtained from a scientific literature reference;
(b) an in vitro method comprising incubating RBCs of a known initial HbA1c fraction (A1) in a solution of known glucose concentration (G1) for a time (T1) to measure a final HbA1c fraction (A2) and calculating said kg; and
(c) an in vivo method comprising administering tagged RBCs of a known initial HbA1c fraction (A3) to said subject, retrieving said tagged RBCs after a time (T2) to measure a final HbA1c fraction (A4), and calculating said kg based on an estimated average glucose (eAG) of said subject.

### Claim 4 (depends on 2)

The method of claim 2, wherein said T0 is determined by a process comprising:
(a) applying an identifiable stimulus to an RBC cohort in bone marrow at a start time (Tstart), wherein said stimulus is selected from the group consisting of: (i) administering a traceable precursor, said precursor being 59Fe or 14C-glycine, and (ii) administering an erythropoietic stimulant, said stimulant being erythropoietin (EPO);
(b) monitoring circulating peripheral blood to detect a first appearance of said RBC cohort at an end time (Tend); and
(c) defining T0 as the time difference between Tend and Tstart.

### Claim 5 (depends on 1)

The method of claim 1, wherein said whole-blood RBC age probability density function, PDFAge(t), is defined by a method selected from the group consisting of: (a) direct measurement of RBC ages from said subject; and (b) reconstructing said PDFAge(t) by applying a mathematical survival function model to a measured survival rate, wherein said survival rate is obtained by (i) administering a tagged cohort of RBCs, said tagged cohort being tagged by biotin or a radioactive element, to said subject, (ii) sampling blood at a plurality of different time points, and (iii) measuring a change in the tagged RBC population over time.

### Claim 6 (depends on 3)

The method of claim 3, wherein said estimated average glucose (eAG) is determined from at least one data source selected from the group consisting of: an average of said {Ai}, a whole-blood HbA1c measurement, a continuous glucose monitoring data log, and an average of one or more fasting blood glucose measurements.

### Claim 7 (depends on 1)

The method of claim 1, wherein said selected bin width ΔA is determined as a function of said N by applying a statistical histogram binning rule to said first RBC HbA1c distribution, PDFHBA1c(A).

### Claim 8 (depends on 1)

The method of claim 1, wherein said time resolution ΔT is determined as a function of said selected bin width ΔA and an estimated glycation rate, said glycation rate being derived from said RBC glycation model A(t) and said historical glucose concentration trajectory, G(τ).

### Claim 9 (depends on 1)

The method of claim 1, wherein said deviation metric comprises any mathematical function that quantifies a dissimilarity between said first RBC HbA1c distribution and said subsequent (reference or second) RBC HbA1c distribution.

### Claim 10 (depends on 1)

The method of claim 1, wherein said step (g) of iteratively modifying said candidate G(τ) further comprises applying a mathematical regularization function to said G(τ) to enforce smoothness and stabilize the reconstruction against noise.

### Claim 11 (depends on 1)

The method of claim 1, wherein said step (a) of obtaining said plurality of {Ai} is performed by an assay or technique capable of determining a glycated hemoglobin (HbA1c) fraction within a single red blood cell, said assay or technique including, but not limited to, High-Performance Liquid Chromatography (HPLC), capillary electrophoresis, immunoassay, mass spectrometry, Raman-based methods, transient absorption microscopy, absorption spectroscopy, or optical microscopy.

### Claim 12 (depends on 1)

The method of claim 1, wherein said step (a) of obtaining said plurality of {Ai} is performed by Resonant-Enhanced Color-Resolved Third-Harmonic-Generation (RE-cTHGM) microscopy, said microscopy method comprising:
(a) exciting a single red blood cell with single broadband laser beam or wavelength-tunable laser beam;
(b) generating a color-resolved third-harmonic-generation (THG) signal from said red blood cell, wherein said THG signal is resonantly enhanced based on the distinct absorption spectra of hemoglobin (Hb) and glycated hemoglobin (HbA1c);
(c) partitioning said resonantly enhanced THG signal into at least two distinct spectral channels; and
(d) computing said HbA1c fraction {Ai} for said single red blood cell from a relative signal intensity between said at least two spectral channels, wherein a first spectral channel is selected to be more sensitive to non-glycated hemoglobin (Hb) and a second spectral channel is selected to be more sensitive to glycated hemoglobin (HbA1c).

### Claim 13

A system for analyzing a subject's historical glycemic status, the system comprising: (a) a data processing terminal comprising one or more processors; and (b) a non-transitory machine-readable medium operatively coupled to said one or more processors, said medium storing instructions that, when executed, cause said data processing terminal to perform at least the following steps: (i) receiving a first RBC HbA1c distribution, PDFHBA1c(A), generated from a plurality of HbA1c fractions, {Ai}, obtained from N RBCs; (ii) defining a whole-blood RBC age probability density function, PDFAge(t); (iii) defining an RBC glycation model, A(t), that provides a deterministic mapping between a historical glucose concentration trajectory, G(τ), and a corresponding HbA1c fraction; and (iv) generating a subsequent RBC HbA1c distribution based on said PDFAge(t) and said A(t).

### Claim 14 (depends on 1, 13)

The system of claim 13, wherein said instructions, when executed, further cause said data processing terminal to perform the method of claim 1.

### Claim 15 (depends on 2, 13)

The system of claim 13, wherein said instructions, when executed, further cause said data processing terminal to perform the method of claim 2.

### Claim 16 (depends on 13)

The system of claim 13, further comprising a data acquisition interface configured to receive said plurality of {Ai} from an external assay.

### Claim 17 (depends on 16)

The system of claim 16, wherein said external assay comprises a Resonant-Enhanced Color-Resolved Third-Harmonic-Generation (RE-cTHGM) instrument operatively coupled to said data acquisition interface.

### Claim 18 (depends on 1)

The method of claim 1, further comprising storing said reconstructed historical glucose concentration trajectory, G(τ), in a subject's electronic data record for clinical review or longitudinal follow-up.
